Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • When typing in this field, a list of search results will appear and be automatically updated as you type.

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

Vascular Graft Solutions Acquires the Intellectual Property Developed by Kipsbay Medical Inc.


News provided by

Vascular Grafts Solutions

06 Jan, 2020, 09:00 IST

Share this article

Share toX

Share this article

Share toX

TEL AVIV, Israel, Jan. 6, 2020 /PRNewswire/ -- Vascular Graft Solutions (VGS) announces on the acquisition of several patent families from NEOGRAFT Technologies Inc. which include patents that were previously developed and owned by Kipsbay Medical Inc, a pioneer in the field of venous external stenting and vascular engineering.

Continue Reading
VGS Ltd. Family of External Suppor Products
VGS Ltd. Family of External Suppor Products

The patents portfolio, which includes more than 25 patents in the U.S, Europe, Canada and, Japan, will broaden the existing portfolio and the protection on the unique suite of technologies developed and commercialized by the company for coronary bypass, peripheral vascular reconstruction, and repair of high flow AV fistula in dialysis patients.

"Strengthening our IP portfolio, coupled with the evolution of our clinical data, position VGS as a global leader in the field of advanced vascular engineering", said Eyal Orion, Founder and CEO of VGS. "We continue to be committed to patients with cardiovascular diseases and invest significant resources to develop novel solutions that will improve cardiovascular surgery and patient' outcome. The new patents and know-how, which are based on the extensive research done by the renowned cardiac surgeon Prof. Peter Zilla and his team from Cape Town, will enable us to explore new approaches to create blood vessel which are resistant to the development of atherosclerosis." 

About VGS

VGS is a leading developer of innovative technologies to improve surgical revascularization, vascular reconstruction procedures and arteriovenous fistula in hemodialysis patients. VGS is headquartered in Tel-Aviv, Israel with distribution channels around Europe, South Africa, Mexico and Australia.

CONTACT:

Rotem Katzenellenbogen,
VP Business Development VGS
+972-3-549-9054
[email protected]

SOURCE Vascular Grafts Solutions

Modal title

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2026 Cision US Inc.